1. Home /
    2. Altai Protocol Library /
  2. New Drug: Umbralisib for relapsed/refractory follicular and marginal zone lymphoma

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Drug: Umbralisib for relapsed/refractory follicular and marginal zone lymphoma

New Drug: Umbralisib for relapsed/refractory follicular and marginal zone lymphoma
Study:
  • Open-label phase II trial (UNITY-NHL), Umbralisib 800 mg PO daily
  • Relapsed/refractory disease, non-transplant candidates, had received anti-CD20
  • Marginal zone (n=69, MZL), Follicular (n=117, FL, non-grade IIIB)
Efficacy:
  • CR/ORR: 16%/49% in MZL, 5%/45% in FL
  • Median DoR: NR [10.3 mos – NE] in MZL, 11.1 mos [8.3-15.6 mos] in FL
  • Median PFS: NR [12.1 mos – NE] in MZL, 10.6 mos [7.2-13.7 mos] in FL
Safety:
  • Grade 3-4 AEs: Diarrhea (10%), neutropenia (12%), increased ALT (7%)

Blood (2020) 136 (Supplement 1): 34–35

Zinzani PL, et al. Umbralisib, the Once Daily Dual Inhibitor of PI3Kδ and Casein Kinase-1ε Demonstrates Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: Results from the Phase 2 Global Unity-NHL Trial

https://doi.org/10.1182/blood-2020-134851

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More